5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

NCT01652781 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine

Sponsor

Seoul St. Mary's Hospital

Collaborators

[object Object]